Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Claya vs T2D.com

Claya
Graded #268

Higher grade

vs+9.799999999999997
T2D.com
Graded #475

Lower grade

The verdict

Claya takes it — 62.8/100 to 53/100.

Claya grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Claya is a direct-to-consumer telehealth platform offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms — a wider format range than most competitors.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueClaya +13
42
29
Dose & formulationClaya +11
75
64
Clinical oversightClaya +13
82
69
Labs & monitoringClaya +1
53
52
FulfillmentClaya +9
67
58
Contract termsClaya +6
61
55
Claya · left barT2D.com · right bar

The numbers

MetricClayaT2D.com
WeighScore62.8/10053/100
GradeCC
Scorecard rank#268#475
Semaglutide$299/mo (compounded)$999/mo (starting dose, compounded)
Tirzepatide$299/mo (compounded)$999/mo (starting dose, compounded)
CoverageCoverage not published1 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Claya

Graded #268 · C

Strengths

  • Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
  • Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
  • Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
  • Weight-loss money-back guarantee published on the homepage
  • Free expedited shipping included in the monthly price

Where it loses points

  • States-served list not disclosed — you must check at checkout
  • LegitScript certification status not displayed
  • Corporate legal entity not disclosed on the site or privacy policy
  • Oral compounded tablets have weaker efficacy data than injectable semaglutide
  • Intro pricing is higher at refill ($299), erasing the first-month advantage
T2D.com

Graded #475 · C

Strengths

  • Built specifically for type 2 diabetic and pre-diabetic patients
  • Integrated service — prescriber, pharmacy, and delivery handled in one flow
  • Offers both compounded semaglutide and compounded tirzepatide
  • Temperature-controlled home delivery via UPS or FedEx
  • Ongoing prescriber monitoring and support included

Where it loses points

  • No pricing published on the public website — must register to see costs
  • No states list published on the site
  • Newer brand with limited independent reviews
  • Compounded only — no brand-name Ozempic, Wegovy, or Mounjaro

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard